April 2009
Volume 50, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2009
Micropulse versus Bevacizumab in Central Serous Retinopathy
Author Affiliations & Notes
  • M. J. Koss
    Ophthalmology, University of Frankfurt, Frankfurt, Germany
  • A. Bauch
    Ophthalmology, University of Frankfurt, Frankfurt, Germany
  • F. H. Koch
    Ophthalmology, University of Frankfurt, Frankfurt, Germany
  • Footnotes
    Commercial Relationships  M.J. Koss, None; A. Bauch, None; F.H. Koch, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science April 2009, Vol.50, 227. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      M. J. Koss, A. Bauch, F. H. Koch; Micropulse versus Bevacizumab in Central Serous Retinopathy. Invest. Ophthalmol. Vis. Sci. 2009;50(13):227.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Methods: : 19 eyes of 19 patients (43.8 years, all male) with acute (n=7) and chronic (n=12) CSR were followed for 10 months after micro-pulsed 810nm focal diode lasercoagulation (group1; n=8), initial 1.5mg bevacizumab intravitreal injection (group2; n=5), or as a control group (group3; n=6). EDTRS visual acuity score, subthreshold static automated 10° perimetry, central macular thickness (CMT) with optical coherence tomography, and fluorescein angiography were performed at baseline, 6 weeks, 6 and 10 months post initial treatment.

Results: : VA increased significantly in group I and II (+6 and +5 letters, respectively, versus -4) with a change in spherical equivalent of -1.75dpt in group1. Mean perimetric deficit improved in group1 by 2.2, and by 5 in group2, whereas a decrease of over 10 dbl in group3. CMT and leackage in FA improved significantly in both treatment groups in comparison to the control. No adverse events were noticed.

Clinical Trial: : www.clinicaltrials.gov NCT00802906

Keywords: laser • vascular endothelial growth factor • clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×